Your browser doesn't support javascript.
loading
Lipid Nanoparticles Deliver the Therapeutic VEGFA mRNA In Vitro and In Vivo and Transform Extracellular Vesicles for Their Functional Extensions.
Nawaz, Muhammad; Heydarkhan-Hagvall, Sepideh; Tangruksa, Benyapa; González-King Garibotti, Hernán; Jing, Yujia; Maugeri, Marco; Kohl, Franziska; Hultin, Leif; Reyahi, Azadeh; Camponeschi, Alessandro; Kull, Bengt; Christoffersson, Jonas; Grimsholm, Ola; Jennbacken, Karin; Sundqvist, Martina; Wiseman, John; Bidar, Abdel Wahad; Lindfors, Lennart; Synnergren, Jane; Valadi, Hadi.
Afiliação
  • Nawaz M; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 41346, Sweden.
  • Heydarkhan-Hagvall S; BioPharmaceuticals R&D, Early Cardiovascular, Renal and Metabolism (CVRM), Bioscience Cardiovascular, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.
  • Tangruksa B; Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, SE-54128, Sweden.
  • González-King Garibotti H; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 41346, Sweden.
  • Jing Y; Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, SE-54128, Sweden.
  • Maugeri M; BioPharmaceuticals R&D, Early Cardiovascular, Renal and Metabolism (CVRM), Bioscience Cardiovascular, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.
  • Kohl F; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.
  • Hultin L; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 41346, Sweden.
  • Reyahi A; Safety Innovations, Clinical Pharmacology and Safety Sciences, R&D AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.
  • Camponeschi A; BioPharmaceuticals R&D, Discovery Sciences, Translational Genomics, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.
  • Kull B; Department of Medical Biochemistry and Biophysics, Karolinska Institute, Solna, Stockholm, 17177, Sweden.
  • Christoffersson J; BioPharmaceuticals R&D, Clinical Pharmacology and Safety Science, Imaging and Data Analytics, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.
  • Grimsholm O; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 41346, Sweden.
  • Jennbacken K; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 41346, Sweden.
  • Sundqvist M; BioPharmaceuticals R&D, Early Cardiovascular, Renal and Metabolism (CVRM), Bioscience Cardiovascular, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.
  • Wiseman J; BioPharmaceuticals R&D, Early Cardiovascular, Renal and Metabolism (CVRM), Bioscience Cardiovascular, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.
  • Bidar AW; Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, SE-54128, Sweden.
  • Lindfors L; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 41346, Sweden.
  • Synnergren J; Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, 1090, Austria.
  • Valadi H; BioPharmaceuticals R&D, Early Cardiovascular, Renal and Metabolism (CVRM), Bioscience Cardiovascular, AstraZeneca, Gothenburg, Mölndal, 43183, Sweden.
Adv Sci (Weinh) ; 10(12): e2206187, 2023 04.
Article em En | MEDLINE | ID: mdl-36806740

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vesículas Extracelulares / COVID-19 Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vesículas Extracelulares / COVID-19 Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article